In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Multidrug-Resistant Pathogens in Wound Care
An Enemy in the Microbiome?
- Rare Genodermatoses: From Diagnosis to Treatment
Darier’s Disease, also known as Follicular Keratosis – Update 2026
- Psychedelic-assisted therapy
Current status of PAT
- Osgood-Schlatter Disease
Clinical Presentation, Diagnosis, and Treatment
- Cardiovascular Risk in Rheumatoid Arthritis
What is the most dangerous thing for RA?
- Antisense oligonucleotide for severe hypertriglyceridemia
Reduced Incidence of Acute Pancreatitis
- Hereditary Transthyretin Amyloidosis with Polyneuropathy
New Treatment Options for ATTRv-PN
- Type 1 Diabetes: A New Disease-Modifying Treatment Approach